Discovery of a Novel Compound with Anti-Venezuelan Equine Encephalitis Virus Activity That Targets the Nonstructural Protein 2

English version České info

Alphaviruses occur worldwide, causing significant diseases such as encephalitis or arthritis in humans and animals. In addition, some alphaviruses, such as VEEV, pose a biothreat due to their high infectivity and lack of available treatments. To discover small molecule inhibitors with lead development potential, we used a cell-based assay to screen 348,140 compounds for inhibition of a VEEV-induced cytopathic effect. The screen revealed a scaffold with high inhibitory VEEV cellular potency and low cytotoxicity liability. While most previously reported anti-alphavirus compounds inhibit host proteins, evidence supported that this scaffold targeted the VEEV nsP2 protein, and that inhibition was associated with viral replication. Interestingly, compound resistance studies with VEEV mapped activity to the N-terminal domain of nsP2, to which no known function has been attributed. Ultimately, this discovery has delivered a small molecule-derived class of potent VEEV inhibitors whose activity is coupled to the nsP2 viral protein, a novel target with a previously unestablished biological role that is now implicated in viral replication.

Vyšlo v časopise: Discovery of a Novel Compound with Anti-Venezuelan Equine Encephalitis Virus Activity That Targets the Nonstructural Protein 2. PLoS Pathog 10(6): e32767. doi:10.1371/journal.ppat.1004213
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1004213

Souhrn

Zdroje

1. WeaverSC, BarrettAD (2004) Transmission cycles, host range, evolution and emergence of arboviral disease. Nature reviews Microbiology 10: 789–801 doi:1038/nrmicro1006

2. AguilarPV, Estrada-FrancoJG, Navarro-LopezR, FerroC, HaddowAD, et al. (2011) Endemic Venezuelan equine encephalitis in the Americas: hidden under the dengue umbrella. Future Virol 6: 721–740.

3. PaesslerS, WeaverSC (2009) Vaccines for Venezuelan equine encephalitis. Vaccine 27 Suppl 4: D80–85.

4. FineDL, JenkinsE, MartinSS, GlassP, ParkerMD, et al. (2010) A multisystem approach for development and evaluation of inactivated vaccines for Venezuelan equine encephalitis virus (VEEV). J Virol Methods 163: 424–432.

5. BergeTO, BanksIS, TigerttWD (1961) Attenuation of venezuelan equine encephalomyelitis virus by in vitro cultivation in guinea-pig heart cells. Am J Epidemiol 73: 209–218.

6. PittmanPR, MakuchRS, MangiaficoJA, CannonTL, GibbsPH, et al. (1996) Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine 14: 337–343.

7. JahrlingPB, StephensonEH (1984) Protective efficacies of live attenuated and formaldehyde-inactivated Venezuelan equine encephalitis virus vaccines against aerosol challenge in hamsters. J Clin Microbiol 19: 429–431.

8. PrattWD, GibbsP, LouiseM, PittM, SchmaljohnAL (1998) Use of telemetry to assess vaccine induced protection against parenteral and aerosol infections of Venezuelan equine encephalitis virus in non-human primates. Vaccine 16: 1056–1064.

9. MarklandW, McQuaidTJ, JainJ, KwongAD (2000) Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrobial Agents and Chemotherapy 44: 859–866.

10. JulanderJG, BowenRA, RaoJR, DayC, ShaferK, et al. (2008) Treatment of Venezuelan equine encephalitis virus infection with (−)-carbodine. Antiviral Res 80: 309–315.

11. SelvamP, VijayalakshimiP, SmeeDF, GowenBB, JulanderJG, et al. (2007) Novel 3-sulphonamido-quinazolin-4(3H)-one derivatives: microwave-assisted synthesis and evaluation of antiviral activities against respiratory and biodefense viruses. Antivir Chem Chemother 18: 301–305.

12. Kehn-HallK, NarayananA, LundbergL, SampeyG, PinkhamC, et al. (2012) Modulation of GSK-3beta activity in Venezuelan equine encephalitis virus infection. PLoS One 7: e34761.

13. FineDL, RobertsBA, TeeheeML, TerpeningSJ, KellyCL, et al. (2007) Venezuelan equine encephalitis virus vaccine candidate (V3526) safety, immunogenicity and efficacy in horses. Vaccine 10.1016/j.vaccine.2006.10.030 1868–1876.

14. PrattWD, DavisNL, JohnstonRE, SmithJF (2003) Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models. Vaccine 21: 3854–3862.

15. PauwelsR, AndriesK, DesmyterJ, ScholsD, KuklaMJ, et al. (1990) Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343: 470–474.

16. JulanderJG, SkirpstunasR, SiddharthanV, ShaferK, HoopesJD, et al. (2008) C3H/HeN mouse model for the evaluation of antiviral agents for the treatment of Venezuelan equine encephalitis virus infection. Antiviral Res 78: 230–241.

17. SawickiDL, SawickiSG (1980) Short-lived minus-strand polymerase for Semliki Forest virus. Journal of Virology 34: 108–118.

18. HardyFM (1959) The growth of Venezuelan equine encephalomyelitis virus in various tissue cultures. Am J Hyg 70: 21–27.

19. SchererWF, EllsworthCA, VenturaAK (1971) Studies of viral virulence. II. Growth and adsorption curves of virulent and attenuated strains of Venezuelan encephalitis virus in cultured cells. Am J Pathol 62: 211–219.

20. Gomez de CedronM, EhsaniN, MikkolaML, GarciaJA, KaariainenL (1999) RNA helicase activity of Semliki Forest virus replicase protein NSP2. FEBS Lett 448: 19–22.

21. RikkonenM, PeranenJ, KaariainenL (1994) ATPase and GTPase activities associated with Semliki Forest virus nonstructural protein nsP2. J Virol 68: 5804–5810.

22. GorbalenyaAE, KooninEV (1993) Helicases - Amino-Acid-Sequence Comparisons and Structure-Function-Relationships. Current Opinion in Structural Biology 3: 419–429.

23. LullaV, MeritsA, SarinP, KaariainenL, KeranenS, et al. (2006) Identification of mutations causing temperature-sensitive defects in Semliki Forest virus RNA synthesis. Journal of Virology 80: 3108–3111.

24. HardyWR, HahnYS, de GrootRJ, StraussEG, StraussJH (1990) Synthesis and processing of the nonstructural polyproteins of several temperature-sensitive mutants of Sindbis virus. Virology 177: 199–208.

25. RussoAT, WhiteMA, WatowichSJ (2006) The crystal structure of the Venezuelan equine encephalitis alphavirus nsP2 protease. Structure 14: 1449–1458.

26. ZhangD, TozserJ, WaughDS (2009) Molecular cloning, overproduction, purification and biochemical characterization of the p39 nsp2 protease domains encoded by three alphaviruses. Protein expression and purification 64: 89–97.

27. SawickiDL, PerriS, PoloJM, SawickiSG (2006) Role for nsP2 proteins in the cessation of alphavirus minus-strand synthesis by host cells. J Virol 80: 360–371.

28. AkhrymukI, KulemzinSV, FrolovaEI (2012) Evasion of the innate immune response: the Old World alphavirus nsP2 protein induces rapid degradation of Rpb1, a catalytic subunit of RNA polymerase II. J Virol 86: 7180–7191.

29. Kehn-HallK, NarayananA, LundbergL, SampeyG, PinkhamC, et al. (2012) Modulation of GSK-3beta activity in Venezuelan equine encephalitis virus infection. PLoS One 10.1371/journal.pone.0034761 e34761.

30. HugginsJW, JahrlingPB, RillW, LindenCD (1983) Characterization of the binding of the TC-83 strain of Venezuelan Equine encephalomyelitis virus to BW-J-M, a mouse macrophage-like cell line. J Gen Virol 64(Pt 1): 149–157.

31. BernardKA, KlimstraWB, JohnstonRE (2000) Mutations in the E2 glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, low morbidity, and rapid clearance from blood of mice. Virology 276: 93–103.

32. ChungDH, JonssonCB, MaddoxC, McKellipSN, MooreBP, et al. (2010) HTS-driven discovery of new chemotypes with West Nile Virus inhibitory activity. Molecules 15: 1690–1704.

33. ZhangJH, ChungTD, OldenburgKR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomolecular Screening 67–73.

34. DowerK, RubinsKH, HensleyLE, ConnorJH (2011) Development of Vaccinia reporter viruses for rapid, high content analysis of viral function at all stages of gene expression. Antiviral Res 91: 72–80.

35. WhitlowZW, ConnorJH, LylesDS (2006) Preferential translation of vesicular stomatitis virus mRNAs is conferred by transcription from the viral genome. J Virol 80: 11733–11742.

36. ChungDH, MooreBP, MatharuDS, GoldenJE, MaddoxC, et al. (2013) A cell based high-throughput screening approach for the discovery of new inhibitors of respiratory syncytial virus. Virol J 10: 19.

37. GuptaCK, LeszczynskiJ, GuptaRK, SiberGR (1996) Stabilization of respiratory syncytial virus (RSV) against thermal inactivation and freeze-thaw cycles for development and control of RSV vaccines and immune globulin. Vaccine 14: 1417–1420.